Thomas Gillingwater

List of Publications by Year
in descending order

Version: 2024-02-01

164 papers	10,046 citations	31902 53 h-index	43802 91 g-index
175 all docs	175 docs citations	175 times ranked	11402 citing authors

#	Article	IF	Citations
1	Anatomical, functional and biomechanical review of the glenoid labrum. Journal of Anatomy, 2022, 240, 761-771.	0.9	4
2	The mitochondrial protein Sideroflexin 3 (SFXN3) influences neurodegeneration pathways inÂvivo. FEBS Journal, 2022, 289, 3894-3914.	2.2	2
3	A call to introduce newborn screening for spinal muscular atrophy (SMA) in Scotland. Scottish Medical Journal, 2022, , 003693302210789.	0.7	2
4	264th ENMC International Workshop: Multi-system involvement in spinal muscular atrophy Hoofddorp, the Netherlands, November 19th â€“ 21st 2021. Neuromuscular Disorders, 2022, 32, 697-705.	0.3	4
5	SMN Depleted Mice Offer a Robust and Rapid Onset Model of Nonalcoholic Fatty Liver Disease. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 354-377.e3.	2.3	16
6	Automated in vivo drug screen in zebrafish identifies synapse-stabilising drugs with relevance to spinal muscular atrophy. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	12
7	Revisiting the role of mitochondria in spinal muscular atrophy. Cellular and Molecular Life Sciences, 2021, 78, 4785-4804.	2.4	14
8	Terminal Schwann cells at the human neuromuscular junction. Brain Communications, 2021, 3, fcab081.	1.5	20
9	Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine. Cell Reports Medicine, 2021, 2, 100346.	3.3	57
10	Maximising returns: combining newborn screening with gene therapy for spinal muscular atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, jnnp-2021-327459.	0.9	1
11	Neutralisation of SARSâ€CoVâ€2 by anatomical embalming solutions. Journal of Anatomy, 2021, 239, 1221-1225.	0.9	5
12	Confocal Endomicroscopy of Neuromuscular Junctions Stained with Physiologically Inert Protein Fragments of Tetanus Toxin. Biomolecules, 2021, 11, 1499.	1.8	0
13	Improving surgical training: Establishing a surgical anatomy programme in Scotland. International Journal of Surgery, 2021, 96, 106172.	1.1	2
14	Temporal Profiling of the Cortical Synaptic Mitochondrial Proteome Identifies Ageing Associated Regulators of Stability. Cells, 2021, 10, 3403.	1.8	0
15	Phospho-RNA sequencing with circAID-p-seq. Nucleic Acids Research, 2021, , .	6.5	0
16	Motor neuron translatome reveals deregulation of SYNGR4 and PLEKHB1 in mutant TDP-43 amyotrophic lateral sclerosis models. Human Molecular Genetics, 2020, 29, 2647-2661.	1.4	15
17	aNMJ-morph: a simple macro for rapid analysis of neuromuscular junction morphology. Royal Society Open Science, 2020, 7, 200128.	1.1	19
18	SMN-primed ribosomes modulate the translation of transcripts related to spinal muscular atrophy. Nature Cell Biology, 2020, 22, 1239-1251.	4.6	52

#	Article	IF	Citations
19	Comparative anatomy of the mammalian neuromuscular junction. Journal of Anatomy, 2020, 237, 827-836.	0.9	36
20	Renal pathology in a mouse model of severe Spinal Muscular Atrophy is associated with downregulation of Glial Cell-Line Derived Neurotrophic Factor (GDNF). Human Molecular Genetics, 2020, 29, 2365-2378.	1.4	13
21	Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy. Human Molecular Genetics, 2020, 29, 2674-2683.	1.4	23
22	Immature Dentate Granule Cells Require Ntrk2/Trkb for the Formation of Functional Hippocampal Circuitry. IScience, 2020, 23, 101078.	1.9	14
23	COVIDâ€19 and anatomy: Stimulus and initial response. Journal of Anatomy, 2020, 237, 393-403.	0.9	74
24	Anatomical sciences at the University of Edinburgh: Initial experiences of teaching anatomy online. Translational Research in Anatomy, 2020, 19, 100065.	0.3	22
25	Neuromuscular junctions are stable in patients with cancer cachexia. Journal of Clinical Investigation, 2020, 130, 1461-1465.	3.9	35
26	Lamin A/C dysregulation contributes to cardiac pathology in a mouse model of severe spinal muscular atrophy. Human Molecular Genetics, 2019, 28, 3515-3527.	1.4	9
27	Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2019, 6, 1519-1532.	1.7	72
28	Regional Molecular Mapping of Primate Synapses during Normal Healthy Aging. Cell Reports, 2019, 27, 1018-1026.e4.	2.9	20
29	Robust Comparison of Protein Levels Across Tissues and Throughout Development Using Standardized Quantitative Western Blotting. Journal of Visualized Experiments, 2019, , .	0.2	12
30	Molecular Mechanisms Underlying Sensory-Motor Circuit Dysfunction in SMA. Frontiers in Molecular Neuroscience, 2019, 12, 59.	1.4	24
31	Developmental and degenerative cardiac defects in the Taiwanese mouse model of severe spinal muscular atrophy. Journal of Anatomy, 2018, 232, 965-978.	0.9	16
32	Historical Tropical Forest Reliance amongst the Wanniyalaeto (Vedda) of Sri Lanka: an Isotopic Perspective. Human Ecology, 2018, 46, 435-444.	0.7	9
33	Putting gross anatomy into the curriculum: New anatomy syllabi for nursing and pharmacy students. Anatomical Sciences Education, 2018, 11, 427-428.	2.5	2
34	The Anatomical Society's core anatomy syllabus for undergraduate nursing. Journal of Anatomy, 2018, 232, 721-728.	0.9	36
35	Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy. Drugs, 2018, 78, 293-305.	4.9	53
36	Advances in therapy for spinal muscular atrophy: promises and challenges. Nature Reviews Neurology, 2018, 14, 214-224.	4.9	174

#	Article	IF	Citations
37	Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis. Acta Neuropathologica, 2018, 135, 213-226.	3.9	97
38	Editorial. Journal of Anatomy, 2018, 232, 1-2.	0.9	0
39	Multi-Study Proteomic and Bioinformatic Identification of Molecular Overlap between Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). Brain Sciences, 2018, 8, 212.	1.1	15
40	UBA1/GARS-dependent pathways drive sensory-motor connectivity defects in spinal muscular atrophy. Brain, 2018, 141, 2878-2894.	3.7	29
41	Active Ribosome Profiling with RiboLace. Cell Reports, 2018, 25, 1097-1108.e5.	2.9	51
42	Region-specific depletion of synaptic mitochondria in the brains of patients with Alzheimerâ€™s disease. Acta Neuropathologica, 2018, 136, 747-757.	3.9	87
43	Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy. Human Molecular Genetics, 2018, 27, 2851-2862.	1.4	55
44	Examining the impact of audience response systems on student performance in anatomy education: a randomised controlled trial. Scottish Medical Journal, 2018, 63, 16-21.	0.7	8
45	Interventions Targeting Glucocorticoid-KrÃ¼ppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice. EBioMedicine, 2018, 31, 226-242.	2.7	37
46	riboWaltz: Optimization of ribosome P-site positioning in ribosome profiling data. PLoS Computational Biology, 2018, 14, e1006169.	1.5	132
47	Neurochondrin interacts with the SMN protein suggesting a novel mechanism for Spinal Muscular Atrophy pathology. Journal of Cell Science, 2018, 131, .	1.2	14
48	The role of survival motor neuron protein (SMN) in protein homeostasis. Cellular and Molecular Life Sciences, 2018, 75, 3877-3894.	2.4	125
49	Sideroflexin 3 is a Î±-synuclein-dependent mitochondrial protein that regulates synaptic morphology. Journal of Cell Science, 2017, 130, 325-331.	1.2	19
50	Analysis of gene expression in the nervous system identifies key genes and novel candidates for health and disease. Neurogenetics, 2017, 18, 81-95.	0.7	23
51	Viral delivery of C9ORF72 hexanucleotide repeat expansions in mice lead to repeat length dependent neuropathology and behavioral deficits.. DMM Disease Models and Mechanisms, 2017, 10, 859-868.	1.2	25
52	Editorial â€“ Journal of Anatomy January 2017. Journal of Anatomy, 2017, 230, 1-3.	0.9	1
53	Emerging therapies and challenges in spinal muscular atrophy. Annals of Neurology, 2017, 81, 355-368.	2.8	157
54	Genomic Analyses of Pre-European Conquest Human Remains from the Canary Islands Reveal Close Affinity to Modern North Africans. Current Biology, 2017, 27, 3396-3402.e5.	1.8	62

#	Article	IF	Citations
55	Proteomic mapping of differentially vulnerable pre-synaptic populations identifies regulators of neuronal stability in vivo. Scientific Reports, 2017, 7, 12412.	1.6	34
56	Therapeutic strategies for spinal muscular atrophy: SMN and beyond. DMM Disease Models and Mechanisms, 2017, 10, 943-954.	1.2	87
57	Cellular and Molecular Anatomy of the Human Neuromuscular Junction. Cell Reports, 2017, 21, 2348-2356.	2.9	158
58	Two Cases of Spinal Muscular Atrophy Type II with Eosinophilic Oesophagitis. Journal of Neuromuscular Diseases, 2017, 4, 357-362.	1.1	0
59	InÂVivo Translatome Profiling in Spinal Muscular Atrophy Reveals a Role for SMN Protein in Ribosome Biology. Cell Reports, 2017, 21, 953-965.	2.9	89
60	Survival of motor neurone protein is required for normal postnatal development of the spleen. Journal of Anatomy, 2017, 230, 337-346.	0.9	42
61	Proteomic profiling of neuronal mitochondria reveals modulators of synaptic architecture. Molecular Neurodegeneration, 2017, 12, 77.	4.4	43
62	Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy. PLoS Genetics, 2017, 13, e1006744.	1.5	69
63	Pro-death NMDA receptor signaling is promoted by the GluN2B C-terminus independently of Dapk1. ELife, 2017, 6, .	2.8	52
64	Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy. JCI Insight, 2016, 1, e87908.	2.3	65
65	Vascular <scp>D</scp>efects and <scp>S</scp>pinal <scp>C</scp>ord <scp>H</scp>ypoxia in <scp>S</scp>pinal <scp>M</scp>uscular <scp>A</scp>trophy. Annals of Neurology, 2016, 79, 217-230.	2.8	79
66	Counting the cost of spinal muscular atrophy. Journal of Medical Economics, 2016, 19, 827-828.	1.0	7
67	NMJ-morph reveals principal components of synaptic morphology influencing structureâ€“function relationships at the neuromuscular junction. Open Biology, 2016, 6, 160240.	1.5	99
68	Dawn of a new therapeutic era for spinal muscular atrophy. Lancet, The, 2016, 388, 2964-2965.	6.3	6
69	Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes. Human Molecular Genetics, 2016, 25, ddw269.	1.4	57
70	Commonality amid diversity: Multi-study proteomic identification of conserved disease mechanisms in spinal muscular atrophy. Neuromuscular Disorders, 2016, 26, 560-569.	0.3	30
71	Survival Motor Neuron (SMN) protein is required for normal mouse liver development. Scientific Reports, 2016, 6, 34635.	1.6	54
72	Revealing the secrets of the dead. Lancet, The, 2016, 388, 1974.	6.3	0

#	Article	IF	Citations
73	A new core gross anatomy syllabus for medicine. Anatomical Sciences Education, 2016, 9, 209-210.	2.5	6
74	Selective loss of alpha motor neurons with sparing of gamma motor neurons and spinal cord cholinergic neurons in a mouse model of spinal muscular atrophy. Journal of Anatomy, 2016, 228, 443-451.	0.9	42
75	Restoration of SMN in Schwann cells reverses myelination defects and improves neuromuscular function in spinal muscular atrophy. Human Molecular Genetics, 2016, 25, ddw141.	1.4	32
76	Molecular neuropathology of the synapse in sheep with <scp>CLN</scp>5 Batten disease. Brain and Behavior, 2015, 5, e00401.	1.0	28
77	Anatomy: back in the public spotlight. Lancet, The, 2015, 385, 1825.	6.3	6
78	Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system. Nature Communications, 2015, 6, 6761.	5.8	119
79	VAMP4 Is an Essential Cargo Molecule for Activity-Dependent Bulk Endocytosis. Neuron, 2015, 88, 973-984.	3.8	60
80	Activity-dependent degeneration of axotomized neuromuscular synapses in Wld^S mice. Neuroscience, 2015, 290, 300-320.	1.1	17
81	How far away is spinal muscular atrophy gene therapy?. Expert Review of Neurotherapeutics, 2015, 15, 965-968.	1.4	3
82	Moving towards treatments for spinal muscular atrophy: hopes and limits. Expert Opinion on Emerging Drugs, 2015, 20, 353-356.	1.0	50
83	UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration. Trends in Molecular Medicine, 2015, 21, 622-632.	3.5	108
84	Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse. Acta Neuropathologica Communications, 2015, 3, 53.	2.4	25
85	PTEN Depletion Decreases Disease Severity and Modestly Prolongs Survival in a Mouse Model of Spinal Muscular Atrophy. Molecular Therapy, 2015, 23, 270-277.	3.7	47
86	The Armadillo as a Model for Peripheral Neuropathy in Leprosy. ILAR Journal, 2014, 54, 304-314.	1.8	43
87	Morphological analysis of neuromuscular junction development and degeneration in rodent lumbrical muscles. Journal of Neuroscience Methods, 2014, 227, 159-165.	1.3	64
88	SMN-dependent intrinsic defects in Schwann cells in mouse models of spinal muscular atrophy. Human Molecular Genetics, 2014, 23, 2235-2250.	1.4	62
89	Increased levels of <scp>UCHL</scp>1 are a compensatory response to disrupted ubiquitin homeostasis in spinal muscular atrophy and do not represent a viable therapeutic target. Neuropathology and Applied Neurobiology, 2014, 40, 873-887.	1.8	23
90	A novel mouse model of Warburg Micro Syndrome reveals roles for RAB18 in eye development and organisation of the neuronal cytoskeleton. DMM Disease Models and Mechanisms, 2014, 7, 711-22.	1.2	38

#	Article	IF	Citations
91	The influence of storage parameters on measurement of survival motor neuron (SMN) protein levels: Implications for pre-clinical studies and clinical trials for spinal muscular atrophy. Neuromuscular Disorders, 2014, 24, 973-977.	0.3	6
92	Label-Free Quantitative Proteomic Profiling Identifies Disruption of Ubiquitin Homeostasis As a Key Driver of Schwann Cell Defects in Spinal Muscular Atrophy. Journal of Proteome Research, 2014, 13, 4546-4557.	1.8	39
93	Loss of Glial Neurofascin155 Delays Developmental Synapse Elimination at the Neuromuscular Junction. Journal of Neuroscience, 2014, 34, 12904-12918.	1.7	39
94	Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis. Journal of Visualized Experiments, 2014, , e51162.	0.2	17
95	Dysregulation of ubiquitin homeostasis and Î²-catenin signaling promote spinal muscular atrophy. Journal of Clinical Investigation, 2014, 124, 1821-1834.	3.9	151
96	A Guide to Modern Quantitative Fluorescent Western Blotting with Troubleshooting Strategies. Journal of Visualized Experiments, 2014, , e52099.	0.2	31
97	Studying synapses in human brain with array tomography and electron microscopy. Nature Protocols, 2013, 8, 1366-1380.	5.5	95
98	Label-free proteomics identifies Calreticulin and GRP75/Mortalin as peripherally accessible protein biomarkers for spinal muscular atrophy. Genome Medicine, 2013, 5, 95.	3.6	31
99	Spinal muscular atrophy: going beyond the motor neuron. Trends in Molecular Medicine, 2013, 19, 40-50.	3.5	296
100	Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy. Neuroscience Letters, 2013, 544, 100-104.	1.0	13
101	Mechanisms underlying synaptic vulnerability and degeneration in neurodegenerative disease. Neuropathology and Applied Neurobiology, 2013, 39, 320-334.	1.8	58
102	Executive deficits, not processing speed relates to abnormalities in distinct prefrontal tracts in amyotrophic lateral sclerosis. Brain, 2013, 136, 3290-3304.	3.7	63
103	Total Protein Analysis as a Reliable Loading Control for Quantitative Fluorescent Western Blotting. PLoS ONE, 2013, 8, e72457.	1.1	300
104	Quantitative tractography and tract shape modeling in amyotrophic lateral sclerosis. Journal of Magnetic Resonance Imaging, 2013, 38, 1140-1145.	1.9	16
105	Effect of Limb Lengthening on Internodal Length and Conduction Velocity of Peripheral Nerve. Journal of Neuroscience, 2013, 33, 4536-4539.	1.7	43
106	Combining Comparative Proteomics and Molecular Genetics Uncovers Regulators of Synaptic and Axonal Stability and Degeneration In Vivo. PLoS Genetics, 2012, 8, e1002936.	1.5	54
107	Altered maturation of the primary somatosensory cortex in a mouse model of fragile X syndrome. Human Molecular Genetics, 2012, 21, 2143-2156.	1.4	84
108	Density, calibre and ramification of muscle capillaries are altered in a mouse model of severe spinal muscular atrophy. Neuromuscular Disorders, 2012, 22, 435-442.	0.3	49

#	Article	IF	Citations
109	Morphological Characteristics of Motor Neurons Do Not Determine Their Relative Susceptibility to Degeneration in a Mouse Model of Severe Spinal Muscular Atrophy. PLoS ONE, 2012, 7, e52605.	1.1	32
110	Development of a supported selfâ€directed learning approach for anatomy education. Anatomical Sciences Education, 2012, 5, 114-121.	2.5	44
111	Using induced pluripotent stem cells (iPSC) to model human neuromuscular connectivity: promise or reality?. Journal of Anatomy, 2012, 220, 122-130.	0.9	37
112	Targeting synaptic pathology in multiple sclerosis: fingolimod to the rescue?. British Journal of Pharmacology, 2012, 165, 858-860.	2.7	6
113	WldS Prevents Axon Degeneration through Increased Mitochondrial Flux and Enhanced Mitochondrial Ca2+ Buffering. Current Biology, 2012, 22, 596-600.	1.8	135
114	Retinoid-independent motor neurogenesis from human embryonic stem cells reveals a medial columnar ground state. Nature Communications, 2011, 2, 214.	5.8	81
115	Morphologic and Functional Correlates of Synaptic Pathology in the Cathepsin D Knockout Mouse Model of Congenital Neuronal Ceroid Lipofuscinosis. Journal of Neuropathology and Experimental Neurology, 2011, 70, 1089-1096.	0.9	30
116	ApoE isoform-specific regulation of regeneration in the peripheral nervous system. Human Molecular Genetics, 2011, 20, 2406-2421.	1.4	29
117	Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. Human Molecular Genetics, 2011, 20, 4334-4344.	1.4	89
118	The response of neuromuscular junctions to injury is developmentally regulated. FASEB Journal, 2011, 25, 1306-1313.	0.2	10
119	The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy. DMM Disease Models and Mechanisms, 2011, 4, 457-467.	1.2	113
120	Induction of Cell Stress in Neurons from Transgenic Mice Expressing Yellow Fluorescent Protein: Implications for Neurodegeneration Research. PLoS ONE, 2011, 6, e17639.	1.1	24
121	Age-related motor neuron degeneration in DNA repair-deficient Ercc1 mice. Acta Neuropathologica, 2010, 120, 461-475.	3.9	86
122	Murine cathepsin D deficiency is associated with dysmyelination/myelin disruption and accumulation of cholesteryl esters in the brain. Journal of Neurochemistry, 2010, 112, 193-203.	2.1	28
123	Review: Neuromuscular synaptic vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal muscular atrophy. Neuropathology and Applied Neurobiology, 2010, 36, 133-156.	1.8	123
124	Synaptic Protection in the Brain of WldS Mice Occurs Independently of Age but Is Sensitive to Gene-Dose. PLoS ONE, 2010, 5, e15108.	1.1	12
125	Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy. Human Molecular Genetics, 2010, 19, 420-433.	1.4	98
126	SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Human Molecular Genetics, 2010, 19, 4216-4228.	1.4	105

#	Article	IF	Citations
127	Using mouse cranial muscles to investigate neuromuscular pathology in vivo. Neuromuscular Disorders, 2010, 20, 740-743.	0.3	26
128	Upregulation of PKD1L2 provokes a complex neuromuscular disease in the mouse. Human Molecular Genetics, 2009, 18, 3553-3566.	1.4	16
129	Alternative Splicing Events Are a Late Feature of Pathology in a Mouse Model of Spinal Muscular Atrophy. PLoS Genetics, 2009, 5, e1000773.	1.5	210
130	Molecular correlates of axonal and synaptic pathology in mouse models of Batten disease. Human Molecular Genetics, 2009, 18, 4066-4080.	1.4	88
131	Expression of the neuroprotective slow Wallerian degeneration (Wld S) gene in non-neuronal tissues. BMC Neuroscience, 2009, 10, 148.	0.8	5
132	Protein product of CLN6 gene responsible for variant lateâ€onset infantile neuronal ceroid lipofuscinosis interacts with CRMPâ€2. Journal of Neuroscience Research, 2009, 87, 2157-2166.	1.3	36
133	Transcriptional Regulation of the AP-1 and Nrf2 Target Gene Sulfiredoxin. Molecules and Cells, 2009, 27, 279-283.	1.0	110
134	The importance of exposure to human material in anatomical education: A philosophical perspective. Anatomical Sciences Education, 2008, 1, 264-266.	2.5	36
135	Rapid loss of motor nerve terminals following hypoxiaâ€“reperfusion injury occurs via mechanisms distinct from classic Wallerian degeneration. Journal of Anatomy, 2008, 212, 827-835.	0.9	15
136	Loss of translation elongation factor (eEF1A2) expression in vivo differentiates between Wallerian degeneration and dyingâ€back neuronal pathology. Journal of Anatomy, 2008, 213, 633-645.	0.9	28
137	A neurological phenotype in mice with DNA repair gene Ercc1 deficiency. DNA Repair, 2008, 7, 281-291.	1.3	24
138	Modified cell cycle status in a mouse model of altered neuronal vulnerability (slow Wallerian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302 T	13.9	25
139	VCP binding influences intracellular distribution of the slow Wallerian degeneration protein, WldS. Molecular and Cellular Neurosciences, 2008, 38, 325-340.	1.0	15
140	VAPB interacts with and modulates the activity of ATF6. Human Molecular Genetics, 2008, 17, 1517-1526.	1.4	130
141	mGluR5 Regulates Glutamate-Dependent Development of the Mouse Somatosensory Cortex. Journal of Neuroscience, 2008, 28, 13028-13037.	1.7	71
142	Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Human Molecular Genetics, 2008, 17, 949-962.	1.4	333
143	Identity, developmental restriction and reactivity of extralaminar cells capping mammalian neuromuscular junctions. Journal of Cell Science, 2008, 121, 3901-3911.	1.2	63
144	Synaptic Changes in the Thalamocortical System of Cathepsin D-Deficient Mice. Journal of Neuropathology and Experimental Neurology, 2008, 67, 16-29.	0.9	79

#	Article	IF	Citations
145	Differential Proteomics Analysis of Synaptic Proteins Identifies Potential Cellular Targets and Protein Mediators of Synaptic Neuroprotection Conferred by the Slow Wallerian Degeneration (Wld) Gene. Molecular and Cellular Proteomics, 2007, 6, 1318-1330.	2.5	82
146	Design of a novel quantitative PCR (QPCR)-based protocol for genotyping mice carrying the neuroprotective Wallerian degeneration slow (Wlds) gene. Molecular Neurodegeneration, 2007, 2, 21.	4.4	11
147	Synaptic Vulnerability in Neurodegenerative Disease. Journal of Neuropathology and Experimental Neurology, 2006, 65, 733-739.	0.9	189
148	Delayed synaptic degeneration in the CNS of Wlds mice after cortical lesion. Brain, 2006, 129, 1546-1556.	3.7	55
149	The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells. Human Molecular Genetics, 2006, 15, 625-635.	1.4	44
150	Synaptic Ras GTPase Activating Protein Regulates Pattern Formation in the Trigeminal System of Mice. Journal of Neuroscience, 2006, 26, 1355-1365.	1.7	44
151	Involvement of Protein Kinase A in Patterning of the Mouse Somatosensory Cortex. Journal of Neuroscience, 2006, 26, 5393-5401.	1.7	36
152	A rat model of slow Wallerian degeneration (WldS) with improved preservation of neuromuscular synapses. European Journal of Neuroscience, 2005, 21, 271-277.	1.2	81
153	Progressive Loss of Motor Neuron Function in Wasted Mice: Effects of a Spontaneous Null Mutation in the Gene for the eEF1A2 Translation Factor. Journal of Neuropathology and Experimental Neurology, 2005, 64, 295-303.	0.9	50
154	The slow Wallerian degeneration gene, WldS, inhibits axonal spheroid pathology in gracile axonal dystrophy mice. Brain, 2004, 128, 405-416.	3.7	101
155	Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. European Journal of Neuroscience, 2004, 20, 3092-3114.	1.2	151
156	Neuroprotection after Transient Global Cerebral Ischemia in Wlds Mutant Mice. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 62-66.	2.4	66
157	Axotomy-dependent and -independent synapse elimination in organ cultures of Wlds mutant mouse skeletal muscle. Journal of Neuroscience Research, 2004, 76, 64-75.	1.3	10
158	A Mutation in the Vesicle-Trafficking Protein VAPB Causes Late-Onset Spinal Muscular Atrophy and Amyotrophic Lateral Sclerosis. American Journal of Human Genetics, 2004, 75, 822-831.	2.6	854
159	Myo-GDNF increases non-functional polyinnervation of reinnervated mouse muscle. NeuroReport, 2004, 15, 21-25.	0.6	14
160	The relationship of neuromuscular synapse elimination to synaptic degeneration and pathology: Insights from WldSand other mutant mice. Journal of Neurocytology, 2003, 32, 863-881.	1.6	52
161	Ultrastructural correlates of synapse withdrawal at axotomized neuromuscular junctions in mutant and transgenic mice expressing the Wld gene. Journal of Anatomy, 2003, 203, 265-276.	0.9	21
162	Ageâ€Dependent Synapse Withdrawal at Axotomised Neuromuscular Junctions in Wld s Mutant and Ube4b/Nmnat Transgenic Mice. Journal of Physiology, 2002, 543, 739-755.	1.3	83

#	Article	IF	Citations
163	Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nature Neuroscience, 2001, 4, 1199-1206.	7.1	661
164	Compartmental neurodegeneration and synaptic plasticity in the Wld s mutant mouse. Journal of Physiology, 2001, 534, 627-639.	1.3	90